The B7-CD28 superfamily

Nature Reviews Immunology

Volumn 2, Issue 2, 2002, Pages 116-126

  Sharpe, Arlene H ^a   Freeman, Gordon J ^b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BUTYROPHILIN; CD28 ANTIGEN; CD40 LIGAND; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; ABATACEPT; ANTIBODY CONJUGATE; APOPTOSIS REGULATORY PROTEIN; CD86 ANTIGEN; CD86 PROTEIN, HUMAN; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; INDUCIBLE T CELL CO STIMULATOR; INDUCIBLE T-CELL CO-STIMULATOR; LEUKOCYTE ANTIGEN; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; PDCD1 PROTEIN, HUMAN; T LYMPHOCYTE ANTIGEN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; AUTOIMMUNE DISEASE; CELL PROLIFERATION; EFFECTOR CELL; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; LYMPHOID TISSUE; MEMORY CELL; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; ANIMAL; B LYMPHOCYTE; CELL COMMUNICATION; CELL DIFFERENTIATION; CHEMISTRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PHYSIOLOGY; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTIGENS, SURFACE; APOPTOSIS REGULATORY PROTEINS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CELL COMMUNICATION; CELL DIFFERENTIATION; HUMANS; IMMUNOCONJUGATES; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; T-LYMPHOCYTES;

EID: 0036484220     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri727     Document Type: Review

References (118)

1. Bretscher, P. & Cohn, M. A theory of self-nonself discrimination. Science 169, 1042-1049 (1970).
2. Bretscher, P. A. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc. Natl Acad. Sci. USA 96, 185-190 (1999).
3. Jenkins, M. K. & Schwartz, R. H. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165, 302-319 (1987).
4. Viola, A. & Lanzavecchia, A. T cell activation determined by T cell receptor number and tunable thresholds. Science 273, 104-106 (1996).
5. Sloan-Lancaster, J., Evavold, B. D. & Allen, P. M. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 363, 156-159 (1993).
6. Karandikar, N. J., Vanderlugt, C. L., Bluestone, J. A. & Miller, S. D. Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease. J. Neuroimmunol. 89, 10-18 (1998).
7. Oosterwegel, M. A., Greenwald, R. J., Mandelbrot, D. A., Lorsbach, R. B. & Sharpe, A. H. CTLA-4 and T cell activation. Curr. Opin. Immunol. 11, 294-300 (1999).
8. Salomon, B. & Bluestone, J. A. Complexities of CD28/B7:CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19, 225-252 (2001).
9. Sansom, D. M. CD28, CTLA-4 and their ligands: who does what and to whom? Immunology 101, 169-177 (2000).
10. Chambers, C. A., Kuhns, M. S., Egen, J. G. & Allison, J. P. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19, 565-594 (2001).
11. Hutloff, A. et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 397, 263-266 (1999). Identifies ICOS as a CD28 homologue on activated human T cells and shows that, in conjunction with a TCR signal, ICOS crosslinking upregulates cytokine production, particularly of IL-10 but not of IL-2.
12. Isikawa, K. et al. Prediction of the coding sequence of unidentified human genes. X. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro. DNA Res. 5, 169-176 (1998).
13. Swallow, M. M., Wallin, J. J. & Sha, W. C. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFα. Immunity 11, 423-432 (1999).
14. Ling, V. et al. Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor. J. Immunol. 164, 1653-1657 (2000).
15. Yoshinaga, S. K. et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature 402, 827-832 (1999). Identifies a B7 homologue as the ligand for ICOS and shows an important role for the ICOS pathway in regulating T-cell help for antibody production.
16. Brodie, D. et al. LICOS, a primordial costimulatory ligand? Curr. Biol. 10, 333-336 (2000).
17. Wang, S. et al. Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood 96, 2808-2813 (2000).
18. Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887-3895 (1992).
19. Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1-9 (2000). Identifies a B7 homologue as the receptor for PD-1 and shows that, in conjunction with a TCR signal, this ligand can inhibit T-cell activation and cytokine production.
20. Dong, H., Zhu, G., Tamada, K. & Chen, L. B7-H1, a third member of the B7 family, co-stimulates T cell proliferation and interleukin-10 secretion. Nature Med. 5, 1365-1369 (1999). Identifies a B7 homologue, shows that it is expressed on activated T cells and APCs, and reports the stimulation of T-cell proliferation and cytokine production, particularly of IL-10.
21. Latchman, Y. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunol. 2, 261-268 (2001). Identifies a B7 homologue as a second receptor for PD-1 and shows expression on activated APCs, some non-lymphoid tissues and breast tumours. Shows inhibition of T-cell activation and cytokine production in an antigen-specific system via recruitment of SHP-2.
22. Tseng, S. Y. et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 193, 839-846 (2001).
23. Freeman, G. J. et al. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med. 174, 625-631 (1991).
24. Freedman, A. S. et al. B7, a B cell restricted antigen which identifies pre-activated B cells. J. Immunol. 137, 3260-3267 (1987).
25. Yokochi, T., Holly, R. D. & Clark, E. A. Lymphoblastoid antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid lines, and Burkitt's lymphomas. J. Immunol. 128, 823-827 (1982).
26. Freeman, G. J. et al. Cloning of B7-2: a CTLA4 counter-receptor that costimulates human T cell proliferation. Science 262, 909-911 (1993).
27. Freeman, G. J. et al. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin-2 production. J. Exp. Med. 178, 2185-2192 (1993).
28. Azuma, M. et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 386, 76-79 (1993).
29. Aruffo, A. & Seed, B. Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. Proc. Natl Acad. Sci. USA 84, 8573-8577 (1987).
30. Gross, J. A., St John, T. & Allison, J. P. The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. J. Immunol. 144, 3201-3210 (1990).
31. Brunet, J. F. et al. A new member of the immunoglobulin superfamily - CTLA-4. Nature 328, 267-270 (1987).
32. Linsley, P. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174, 561-569 (1991).
33. Peach, R. J. et al. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J. Exp. Med. 180, 2049-2058 (1994).
34. Linsley, P. S. et al. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J. Exp. Med. 176, 1595-1604 (1992).
35. Linsley, P. S. et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA4 receptors. Immunity 1, 793-801 (1994).
36. Gross, J., Callas, E. & Allison, J. Identification and distribution of the costimulatory receptor CD28 in the mouse. J. Immunol. 149, 380-388 (1992).
37. Linsley, P. et al. Intracellular trafficking of CTLA4 and focal localization towards sites of TCR engagement. Immunity 4, 535-543 (1996).
38. Hathcock, K. S., Laszlo, G., Pucillo, C., Linsley, P. & Hodes, R. J. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180, 631-640 (1994).
39. McAdam, A., Schweitzer, A. & Sharpe, A. H. The role of B7 costimulation in activation and differentiation of CD4 and CD8 T cells. Immunol. Rev. 165, 231-247 (1998).
40. Lenschow, D. J., Walunas, T. L. & Bluestone, J. A CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14, 233-258 (1996).
41. Lanzavecchia, A., Lezzi, G. & Viola, A. From TCR engagement to T cell activation: a kinetic view of T cell behavior. Cell 96, 1-4 (1999).
42. Thompson, C. B. et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl Acad. Sci. USA 86, 1333-1337 (1989).
43. Lucas, P. J. et al. Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. J. Immunol. 154, 5757-5768 (1995).
44. Shahinian, A. et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261, 609-612 (1993).
45. Sperling, A. I. et al. CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. J. Immunol. 151, 3909-3917 (1996).
46. Boise, L., Minn, A., Noel, P. & Thompson, C. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xl. Immunity 3, 87-98 (1995).
47. Walunas, T. L. et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1, 405-413 (1994).
48. Walunas, T. L., Bakker, C. Y. & Bluestone, J. A. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183, 2541-2550 (1996).
49. Krummel, M. & Allison, J. CD28 and CTLA4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459-466 (1995).
50. Brunner, M., Chambers, C. & Allison, J. CTLA-4 mediates inhibition of early events of T cell proliferation. J. Immunol. 162, 5813-5820 (1999).
51. Greenwald, R. J., Boussiotis, V. A., Lorsbach, R. B., Abbas, A. K. & Sharpe, A. H. CTLA-4 regulates induction of anergy in vivo. Immunity 14, 145-155 (2001).
52. Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270, 985-988 (1995).
53. Tivol, E. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541-547 (1995).
54. Mandelbrot, D. A., McAdam, A. J. & Sharpe, A. H. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J. Exp. Med. 189, 435-440 (1999).
55. Perez, V. et al. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6, 411-417 (1997).
56. Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA4 blockade. Science 271, 1734-1736 (1996).
57. Perrin, P. J., Maldonado, J. H., Davis, T. A., June, C. H. & Racke, M. K. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J. Immunol. 157, 1333-1336 (1996).
58. Buonfiglio, D. et al. The T cell activation molecule H4 and the CD28-like molecule ICOS are identical. Eur. J. Immunol. 30, 3463-3467 (2000).
59. Tezuka, K. et al. Identification and characterization of rat AILIM/ICOS, a novel T-cell costimulatory molecule, related to the CD28/CTLA4 family. Biochem. Biophys. Res. Commun. 276, 335-345 (2000).
60. Beier, K. C. et al. Induction, binding specificity and function of human ICOS. Eur. J. Immunol. 30, 3707-3717 (2000).
61. Coyle, A. J. et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 13, 95-105 (2000).
62. Holdorf, A. D., Kanagawa, O. & Shaw, A. S. CD28 and T cell co-stimulation. Rev. Immunogenet. 2, 175-184 (2000).
63. Mages, H. W. et al. Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand. Eur. J. Immunol. 30, 1040-1047 (2000).
64. + T cells. J. Immunol. 165, 5035-5040 (2000).
65. Aicher, A. et al. Characterization of human inducible costimulator ligand expression and function. J. Immunol. 164, 4689-4696 (2000).
66. H1 models.
67. McAdam, A. et al. ICOS is critical for CD40 mediated antibody class switching. Nature 409, 102-105 (2001). Shows a crucial role for ICOS in regulating immunoglobulin isotype class switching and germinal centre formation, by evaluating ICOS-deficient mice (similar to REFS 68,70). Shows that the defects in class switching in ICOS-deficient mice could be overcome by CD40 stimulation, indicating important interactions between these pathways
68. Dong, C. et al. ICOS co-stimulatory receptor is essential for T cell activation and function. Nature 409, 97-101 (2001).
69. Dong, C., Temann, U. A. & Flavell, R. A. Cutting edge: critical role of inducible costimulator in germinal center reactions. J. Immunol. 166, 3659-3662 (2001).
70. Tafuri, A. et al. ICOS is essential for effective T helper cell responses. Nature 409, 105-109 (2001).
71. Yoshinaga, S. K. et al. Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS. Int. Immunol. 12, 1439-1447 (2000).
72. + progenitor cells during differentiation into antigen presenting cells. J. Biol. Chem. 276, 45686-45693 (2001).
73. Riley, J. L. et al. ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement. J. Immunol. 166, 4943-4948 (2001).
74. H2 differentiation, in a model of allergic airway disease. J. Immunol. 167, 1996-2003 (2001).
75. H effector responses.
76. Sporici, R. A. & Perrin, P. J. Costimulation of memory T-cells by ICOS: a potential therapeutic target for autoimmunity? Clin. Immunol. 100, 263-269 (2001).
77. Sperling, A. I. ICOS costimulation: is it the key to selective immunotherapy? Clin. Immunol. 100, 261-262 (2001).
78. Ozkaynak, E. et al. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nature Immunol. 2, 591-596 (2001). Identifies a role for ICOS in acute and chronic rejection using cardiac allograft models. Shows that a combination of anti-ICOS antibody and cyclosporin can lead to long-term graft survival.
79. Furukawa, Y., Mandelbrot, D. A., Libby, P., Sharpe, A. H. & Mitchell, R. N. Association of B7-1 co-stimulation with the development of graft arterial disease. Studies using mice lacking B7-1, B7-2, or B7-1/B7-2. Am. J. Pathol. 157, 473-484 (2000).
80. Kim, K. S. et al. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am. J. Pathol. 158, 977-986 (2001).
81. Borriello, F. et al. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity 6, 303-313 (1997).
82. Rottman, J. B. et al. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nature Immunol. 2, 605-611 (2001).
83. H1-mediated disease EAE and that ICOSL blockade after the onset of EAE can ameliorate clinical disease.
84. Chang, T. C., Jabs, C., Sobel, R. A., Kuchroo, V. K. & Sharpe, A. H. Studies in B7-deficient mice reveal a critical role for B7 costimulation in both the initiation and effector phases of EAE. J. Exp. Med. 190, 733-740 (1999).
85. Perrin, P. J., Lavi, E., Rumbley, C. A., Zekavat, S. A. & Phillips, S. M. Experimental autoimmune meningitis: a novel neurological disease in CD28-deficient mice. Clin. Immunol. 91, 41-49 (1999).
86. Segal, B.M., Dwyer, B. K. & Shevach, E. M. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med. 187, 537-546 (1998).
87. Bettelli, E. et al. IL-10 is is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J. Immunol. 161, 3299-3306 (1998).
88. + T cell responses by ICOS/B7h costimulation. J. Immunol. 167, 132-139 (2001).
89. Shinohara, T. Taniwaki, M., Ishida, Y., Kawaichi, M. & Honjo, T. Structure and chromosomal localization of the human PD-1 gene (PPCP1). Genomics 23, 704-706 (1994).
90. Vibhakar, R., Juan, G., Traganos, F., Darzynkiewicz, Z. & Finger, L. R. Activation-induced expression of human programmed death-1 gene in T-lymphocytes. Exp. Cell Res. 232, 25-28 (1997).
91. Agata, Y. et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8, 765-772 (1996).
92. +) thymocytes. Int. Immunol. 8, 773-780 (1996).
93. Nishimura, H., Honjo, T. & Minato, N. Facilitation of β selection and modification of positive selection in the thymus of PD-1 deficient mice. J. Exp. Med. 191, 891-898 (2000).
94. Bieul, C. C. & Boehm, T. Laser capture microdissection-based expression profiling identifies PD1-ligand as a target of the nude locus gene product. Eur. J. Immunol. 31, 2497-2503 (2001).
95. Eppihimer, M. et al. Expression and regulation of the PD-L1 immuno-inhibitory molecule on microvascular endothelial cells. Microcirculation (in the press).
96. Nishimura, H., Minato, N., Nakano, T. & Honjo, T. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int. Immunol. 10, 1563-1572 (1998).
97. + TCR transgenic mice that escape thymic deletion become activated in the periphery and cause graft-versus-host-like disease.
98. Nishimura, H. et al. Autoimmune dilated cardiomyopathy in PD-1 receptor deficient mice. Science 291, 319-322 (2001).
99. + T cells and is overcome by IL-2. Eur. J. Immunol. (in the press).
100. +CD25(high) regulatory cells in human peripheral blood. J. Immunol. 167, 1245-1253 (2001).
101. Tamura, H. et al. B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood 97, 1809-1816 (2001).
102. Okazaki, T., Nishimura, H. & Honjo, T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting Src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl. Acad. Sci. USA 98, 13866-13871 (2001).
103. Shlapatska, L. M. et al. CD150 association with either the SH2-containing inositol-phosphate or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A J. Immunol. 166, 5480-5487 (2001).
104. + T-cell proliferation, IFN-γ production, and CD8 lytic activity.
105. Ogg, S. L., Komaragiri, M. V. & Mather, I. H. Structural organization and mammary-specific expression of the butyrophilin gene. Mamm. Genome 7, 900-905 (1996).
106. Rhodes, D. A., Stammers, M., Malcherek, G., Beck, S. & Trowsdale, J. The cluster of BTN genes in the extended major histocompatibility complex. Genomics 71, 351-362 (2001).
107. Stammers, M., Rowen, L., Rhodes, D., Trowsdale, J. & Beck, S. BTL-II: a polymorphic locus with homology to the butyrophilin gene family, located at the border of the major histocompatibility complex class II and class III regions in human and mouse. Immunogenetics 51, 373-382 (2000).
108. Linsley, P. S., Peach, R., Gladstone, P. & Bajorath, J. Extending the B7 (CD80) gene family. Protein Sci. 3, 1341-1343 (1994).
109. Mather I. H. A review and proposed nomenclature for major proteins of the milk-fat globule membrane. J. Dairy Sci. 83, 203-247 (2000).
110. Banghart, L. R. et al. Butyrophilin is expressed in mammary epithelial cells from a single-sized messenger RNA as a type I membrane glycoprotein. J. Biol. Chem. 273, 4171-4179 (1998).
111. Seto, M. H., Liu, H. L., Zajchowski, D. A. & Whitlow, M. Protein fold analysis of the B30.2-like domain. Proteins 35, 235-249 (1999).
112. Ishii, T. et al. Carboxy-terminal cytoplasmic domain of mouse butyrophilin specifically associates with a 150-kDa protein of mammary epithelial cells and milk fat globule membrane. Biochim. Biophys. Acta 1245, 285-292 (1995).
113. Peterson, J. A. et al. Milk fat globule glycoproteins in human milk and in gastric aspirates of mother's milk-fed preterm infants. Pediatr. Res. 44, 499-506 (1998).
114. Stefferl, A. et al. Butyrophilin, a milk protein, modulates the encephalitogenic T cell response to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis. J. Immunol. 165, 2859-2865 (2000).
115. Fahrer, A. M., Bazan, J. F., Papathanasiou, P., Nelms, K. A. & Goodnow, C. C. A genomic view of immunology. Nature 409, 836-838 (2001).
116. Ikemizu, S. et al. Structure and dimerization of a soluble form of B7-1. Immunity 12, 51-60 (2000).
117. Schwartz, J. C., Zhang, X., Fedorov, A. A., Nathenson, S. G. & Almo, S. C. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature 410, 604-608 (2001).
118. Stamper, C. C. et al. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 410, 608-611 (2001).